Spearhead Capital Advisors LLC Has $1.20 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)
Spearhead Capital Advisors LLC Has $1.20 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)
Spearhead Capital Advisors LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 85.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,361 shares of the medical instruments supplier's stock after selling 32,521 shares during the quarter. Becton, Dickinson and makes up 1.3% of Spearhead Capital Advisors LLC's holdings, making the stock its 22nd biggest holding. Spearhead Capital Advisors LLC's holdings in Becton, Dickinson and were worth $1,195,000 as of its most recent SEC filing.
根據Speearhead Capital Advisors LLC向美國證券交易委員會(Securities&Exchange Commission)的最新披露,該公司在第三季度減持了Becton,Dickinson and Company(紐約證券交易所代碼:BDX-GET評級)85.8%的股份。該機構投資者在本季度出售了32,521股後,持有這家醫療器械供應商的5,361股股票。Becton、Dickinson和佔Spearhead Capital Advisors LLC所持股份的1.3%,使該股成為其第22大持股。截至最近提交給美國證券交易委員會的文件,先鋒資本顧問公司持有的貝頓-迪金森公司股份價值1,19.5萬美元。
Several other large investors have also bought and sold shares of BDX. Fairfield Bush & CO. bought a new position in Becton, Dickinson and in the first quarter valued at about $114,000. Sequoia Financial Advisors LLC raised its position in Becton, Dickinson and by 11.3% in the first quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier's stock valued at $778,000 after purchasing an additional 297 shares during the last quarter. Brighton Jones LLC raised its position in Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier's stock valued at $368,000 after purchasing an additional 112 shares during the last quarter. Zions Bancorporation N.A. raised its position in Becton, Dickinson and by 13.0% in the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier's stock valued at $134,000 after purchasing an additional 58 shares during the last quarter. Finally, Mather Group LLC. raised its position in Becton, Dickinson and by 26.0% in the first quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier's stock valued at $358,000 after purchasing an additional 278 shares during the last quarter. 87.08% of the stock is owned by institutional investors and hedge funds.
其他幾家大型投資者也買賣了BDX的股票。費爾菲爾德·布什公司在貝克頓、迪金森和第一季度購買了一個新頭寸,估值約為11.4萬美元。紅杉金融顧問公司第一季度將其在Becton,Dickinson的持倉提高了11.3%。紅杉金融顧問公司(Sequoia Financial Advisors LLC)在上個季度額外購買了297股後,現在擁有這家醫療器械供應商2923股股票,價值77.8萬美元。Bright ton Jones LLC在第一季度將其在Becton,Dickinson的頭寸提高了8.8%。Bright ton Jones LLC現在持有這家醫療器械供應商1,383股股票,價值36.8萬美元,上個季度又購買了112股。Zion Bancorporation N.A.在第一季度將其在Becton,Dickinson的頭寸提高了13.0%。Zion Bancorporation N.A.在上個季度額外購買了58股後,現在擁有這家醫療器械供應商504股股票,價值13.4萬美元。最後,Mather Group LLC。第一季度將其在Becton,Dickinson的頭寸提高了26.0%。Mather Group LLC.在上個季度又購買了278股後,現在擁有1346股這家醫療器械供應商的股票,價值35.8萬美元。87.08%的股票由機構投資者和對衝基金持有。
Becton, Dickinson and Trading Down 1.1 %
Becton,Dickinson和Trading下跌1.1%
Shares of BDX stock opened at $245.84 on Friday. The company has a market cap of $69.88 billion, a P/E ratio of 46.38, a PEG ratio of 2.11 and a beta of 0.54. The stock has a 50 day simple moving average of $251.67 and a two-hundred day simple moving average of $244.53. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.63 and a current ratio of 1.07. Becton, Dickinson and Company has a fifty-two week low of $215.90 and a fifty-two week high of $280.62.
上週五,BDX的股票開盤報245.84美元。該公司市值為698.8億美元,市盈率為46.38倍,聚乙二醇率為2.11倍,貝塔係數為0.54。該股的50日簡單移動均線切入位為251.67美元,200日簡單移動均線切入位為244.53美元。該公司的負債權益比率為0.56,速動比率為0.63,流動比率為1.07。Becton,Dickinson and Company的股價為52周低點215.90美元,52周高點為280.62美元。
Becton, Dickinson and Dividend Announcement
貝頓、狄金森和股息公告
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. The ex-dividend date is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a yield of 1.48%. Becton, Dickinson and's dividend payout ratio (DPR) is presently 68.68%.
該公司最近還披露了季度股息,將於3月31日(星期五)支付。3月10日(星期五)登記在冊的股東將獲得0.91美元的股息。除息日期為3月9日(星期四)。這意味着年化股息為3.64美元,收益率為1.48%。Becton,Dickinson and的股息支付率(DPR)目前為68.68%。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several equities analysts have commented on BDX shares. Cowen dropped their target price on Becton, Dickinson and to $255.00 in a research report on Wednesday, November 16th. StockNews.com upgraded Becton, Dickinson and from a "hold" rating to a "buy" rating in a research report on Friday. The Goldman Sachs Group lowered their price objective on Becton, Dickinson and from $319.00 to $272.00 and set a "buy" rating for the company in a research report on Wednesday, November 23rd. Bank of America upgraded Becton, Dickinson and from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $250.00 to $290.00 in a research report on Tuesday, January 3rd. Finally, Evercore ISI lowered their price objective on Becton, Dickinson and to $270.00 in a research report on Wednesday, November 16th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and presently has an average rating of "Moderate Buy" and a consensus target price of $275.70.
幾位股票分析師對BDX的股票發表了評論。Cowen在11月16日週三的一份研究報告中將他們對Becton和Dickinson的目標價下調至255.00美元。在週五的一份研究報告中,StockNews.com將Becton、Dickinson和的評級從持有上調至買入。11月23日週三,高盛夫婦在一份研究報告中將貝頓、狄金森的目標價從319.00美元下調至272.00美元,併為該公司設定了買入評級。1月3日週二,美國銀行在一份研究報告中將Becton、Dickinson和的評級從中性上調至買入,並將其股票目標價從250.00美元上調至290.00美元。最後,Evercore ISI在11月16日星期三的一份研究報告中將他們對Becton,Dickinson的目標價格下調至270.00美元。兩名分析師對該股的評級為持有,六名分析師對該公司的評級為買入。根據MarketBeat.com的數據,Becton、Dickinson和目前的平均評級為“中等買入”,共識目標價為275.70美元。
Becton, Dickinson and Profile
《貝頓、狄金森和肖像》
(Get Rating)
(獲取評級)
Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.
Becton,Dickinson&Co從事醫療用品、設備、實驗室設備和診斷產品的開發、製造和銷售。它通過以下部門開展業務:BD醫療、BD生命科學和BD Intervative。BD醫療部門生產醫療技術和設備,用於幫助改善醫療保健服務。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免費獲取StockNews.com關於Becton、Dickinson和(BDX)的研究報告
- 市場回顧周-1/30-2/3
- 細價股值得嗎?你應該投資細價股嗎?
- Zimmer Biomet盈利節節攀升,增長可能被計入價格
- 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Get Rating).
想看看還有哪些對衝基金持有BDX嗎?訪問HoldingsChannel.com獲取Becton,Dickinson and Company(紐約證券交易所代碼:BDX-GET Rating)的最新13F文件和內幕交易。
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.
接受Becton Dickinson和Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Becton Dickinson和相關公司的最新新聞和分析師評級的每日簡要摘要。